Sanofi (France)
NEWS
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
Sanofi and GlaxoSmithKline reported that their potential COVID-19 booster shot delivered good immune response in its preliminary clinical trials.
The takeover is part of the French biotech giant’s “Play to Win” strategy of growing its global vaccines pipeline through the acquisition of promising projects and companies.
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
BioNTech is on the Fast Track. This morning, the company announced it received Fast Track Designation from the U.S. Food and Drug Administration for its cancer immunotherapy candidate.
The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.
JOBS
IN THE PRESS